Global Iron Drugs Market 2018-2022

  • ID: 4585521
  • Report
  • Region: Global
  • 98 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • PHARMACOSMOS
  • Vifor Pharma
  • MORE
About Iron Drugs

Iron is required to transport oxygen through haemoglobin in red blood cells (RBCs) and oxidize cells through cytochrome. Iron deficiency is a common cause of anaemia. Iron drugs are used to treat people with iron deficiency.

The analysts forecast the Global Iron Drugs Market to grow at a CAGR of 9.27% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the iron drugs market. To calculate the market size, the report considers the revenue generated from iron drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, iron drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • PHARMACOSMOS
  • Vifor Pharma
Market drivers
  • Presence of large patient pool with various disorders
  • For a full, detailed list, view the full report
Market challenges
  • Limitations associated with conventional oral iron therapies
  • For a full, detailed list, view the full report
Market trends
  • Growing focus on emerging economies
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • PHARMACOSMOS
  • Vifor Pharma
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Overview
  • Comparison by product
  • Oral drug - Market size and forecast 2017-2022
  • IV drug - Market size and forecast 2017-2022
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Vendor focus on expanding reach of IV iron drugs
  • Growing focus on emerging economies
  • Counterfeiting of drugs
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • PHARMACOSMOS
  • Vifor Pharma
PART 15: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Related market
Exhibit 02: Market characteristics
Exhibit 03: Global iron drugs market: Segments
Exhibit 04: Market definition: Inclusions and exclusions checklist
Exhibit 05: Market size 2017
Exhibit 06: Validation techniques employed for market sizing 2017
Exhibit 07: Global iron drugs market: Market size and forecast 2017-2022 ($ mn)
Exhibit 08: Global iron drugs market: Year-over-year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition: Five forces 2017
Exhibit 17: Segmentation by product: Market share 2017-2022 (%)
Exhibit 18: Comparison by product
Exhibit 19: Oral drug: Market size and forecast 2017-2022 ($ mn)
Exhibit 20: Oral drug: Year-over-year growth 2018-2022 (%)
Exhibit 21: IV drug: Market size and forecast 2017-2022 ($ mn)
Exhibit 22: IV drug: Year-over-year growth 2018-2022 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Segmentation by geography: Market share 2017-2022 (%)
Exhibit 26: Regional comparison
Exhibit 27: Americas: Market size and forecast 2017-2022 ($ mn)
Exhibit 28: Americas: Year-over-year growth 2018-2022 (%)
Exhibit 29: EMEA: Market size and forecast 2017-2022 ($ mn)
Exhibit 30: EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 31: APAC: Market size and forecast 2017-2022 ($ mn)
Exhibit 32: APAC: Year-over-year growth 2018-2022 (%)
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Vendor landscape
Exhibit 36: Landscape disruption
Exhibit 37: Vendors covered
Exhibit 38: Vendor classification
Exhibit 39: Market positioning of vendors
Exhibit 40: Allergan: Overview
Exhibit 41: Allergan: Operating segments
Exhibit 42: Allergan: Organizational developments
Exhibit 43: Allergan: Geographic focus
Exhibit 44: Allergan: Segment focus
Exhibit 45: Allergan: Key offerings
Exhibit 46: AMAG Pharmaceuticals: Overview
Exhibit 47: AMAG Pharmaceuticals: Business segments
Exhibit 48: AMAG Pharmaceuticals: Organizational developments
Exhibit 49: AMAG Pharmaceuticals: Key offerings
Exhibit 50: Daiichi Sankyo: Overview
Exhibit 51: Daiichi Sankyo: Business segments
Exhibit 52: Daiichi Sankyo: Organizational developments
Exhibit 53: Daiichi Sankyo: Geographic focus
Exhibit 54: Daiichi Sankyo: Segment focus
Exhibit 55: Daiichi Sankyo: Key offerings
Exhibit 56: PHARMACOSMOS: Overview
Exhibit 57: PHARMACOSMOS: Business
Exhibit 58: PHARMACOSMOS: Organizational developments
Exhibit 59: PHARMACOSMOS: Key offerings
Exhibit 60: Vifor Pharma: Overview
Exhibit 61: Vifor Pharma: Business segments
Exhibit 62: Vifor Pharma: Organizational developments
Exhibit 63: Vifor Pharma: Geographic focus
Exhibit 64: Vifor Pharma: Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • PHARMACOSMOS
  • Vifor Pharma
  • MORE
New Report Released: - Global Iron Drugs Market 2018-2022.

The author of the report recognizes the following companies as the key players in the global iron drugs market: Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, PHARMACOSMOS, and Vifor Pharma.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the growing focus on the emerging economies” Several vendors are focusing on emerging economies due to the opportunities for growth. This is because the prevalence of CKD and other diseases such as CHF is increasing in emerging economies such as India, China, and Brazil.

According to the report, one driver influencing this market is the presence of large patient pool with various disorders. The demand for iron drugs is increasing due to the presence of a large patient pool with various disorders. Some risk factors of iron deficiency include CKD, non-dialysis CKD, congestive heart failure (CHF), and postpartum anaemia. The presence of large patient pool with various disorders will drive the growth of the global iron drugs market during the forecast period.

Further, the report states that one challenge affecting this market is the high cost of drugs. The high cost of IV iron drugs is a challenge for the growth of the global iron drugs market. Though IV iron drugs are associated with many advantages over oral iron drugs, they are expensive than oral iron drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • PHARMACOSMOS
  • Vifor Pharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll